medigraphic.com
ISSN 2448-5640 (Impreso)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2019, Número 4

<< Anterior Siguiente >>

Cir Card Mex 2019; 4 (4)


What about current guidelines for coronary revascularization 2018 ESC/EACTS for stable angina? Part I. Stable angina

García-Villarreal OA

Idioma: Ingles.
Referencias bibliográficas: 20
Paginas: 114-119
Archivo PDF: 291.34 Kb.


RESUMEN

La práctica médica actual está soportada en la medicina basada en evidencia. Las guías clínicas tienen este propósito para regular el tratamiento médico y quirúrgico. La enfermedad coronaria es la principal causa de muerte en todo el mundo. A pesar de una serie de indicaciones absolutas para la revascularización coronaria, todavía hay algunas situaciones en las que el proceso de toma de decisiones es difícil de seleccionar. Presentamos aquí los aspectos más notables, destaca al decidir sobre la enfermedad arterial coronaria estable.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The World Health Organization. The 10 top causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accesed the August 19, 2019.

  2. OECD/EU (2016), Health at a Glance: Europe 2016 – State of Health in the EUCycle, OECD Publishing, Paris. http://dx.doi.org/10.1787/9789264265592-en.Accesed the August 19, 2019.

  3. Head SJ, Kaul S, Mack MJ, et al. The rationale for Heart Team decision-makingfor patients with stable, complex coronary artery disease. European Heart Journal2013; 34:2510-8. doi:10.1093/eurheartj/eht059

  4. 2018 ESC/EACTS Guidelines on myocardial revascularization. Sousa-Uva M,Neumann FJ, Ahlsson A, et al. ESC Scientific Document Group. Eur J CardiothoracSurg 2019;55:4-90. doi: 10.1093/ejcts/ezy289.

  5. Ong ATL, Serruys PW, Mohr FW, et al. The SYNergy between percutaneous coronaryinterventions wuth TAXus and cardiac surgery (SYNTAX) study: Desing,rationale, and run-in phase. Am Heart J 2006; 151: 1194-204.

  6. Serryus PW, Morice M-C, Kappetein AP, et al. for the SYNTAX Investigators.Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting forSevere Coronary Artery Disease. N Engl J Med 2009; 360:961-72.

  7. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgeryversus percutaneous coronary intervention in patients with three-vessel diseaseand left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAXtrial. Lancet 2013;381:629-38. doi: 10.1016/S0140-6736(13)60141-5.

  8. Mack M, Baumgarten H, Lytle B. Why surgery won the SYNTAX trial andwhy it matters. J Thorac Cardiovasc Surg 2016;152:1237-40. doi: 10.1016/j.jtcvs.2016.04.083.

  9. Giacoppo D, Colleran R, Cassese S, et al. Percutaneous coronary intervention vscoronary artery bypass grafting in patients with left main coronary artery stenosis:a systematic review and meta-analysis. JAMA Cardiol 2017;2:1079-88.

  10. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgeryfor left main coronary artery disease. N Eng J Med 2011; 364: 1718-27.

  11. Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease:Pathophysiology, clinical consequences, and medical theraphy: Part II. Circulation2003; 108: 1655-61.

  12. Ledru F, Ducimetiere P, Battaglia S, et al. New diagnostic criteria for diabetes andcoronary disease; Insights from an angiographic study. J Am Coll Cardiol 2001;37: 1543-50.

  13. Farkouh ME, Domanski M, Sleeper LA, et al. for the FREEDOM Trial Investigators.Strategies for multivessel revascularization in patients with diabetes. N Eng JMed 2012; 367: 2375-84.

  14. Farkouh ME, Domanski M, Dangas GD, et al. Long-term survival following multivesselrevascularization in patients with diabetes: The FREEDOM Follow-OnStudy. J Am Coll Cardiol 2019;73:629-38.

  15. Kappetein AP, Head SJ, Morice MC, et al. Investigators S. Treatment of complexcoronary artery disease in patients with diabetes: 5-year results comparing outcomesof bypass surgery and percutaneous coronary intervention in the SYNTAXtrial. Eur J Cardiothorac Surg 2013; 43: 1006-13.

  16. Park SJ, Ahn JM, Kim YH, et al. BEST trial Investigators. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015; 372:1204-12.

  17. Esper RB, Farkouh ME, Ribeiro EE, et al. SYNTAX score in patients with diabetesundergoing coronary revascularization in the FREEDOM trial. J Am CollCardiol 2018;72: 2826-37.

  18. Velazquez EJ, Lee KL, Jones RH, et al. STICHES Investigators. Coronary-arterybypass surgery in patients with ischemic cardiomyopathy. N Eng J Med 2016;374: 1511-20.

  19. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL. Revascularization inpatients with multivessel coronary artery disease and severe left ventricular systolicdysfunction: Everolimus-eluting stents versus coronary artery bypass graftingsurgery. Circulation 2016; 133: 2132-40.

  20. Killip T, Passamini E, Davis K. Coronary artery surgery study (CASS): A randomizedtrial of coronary bypass surgery. Eight years follow-up and survival inpatients with reduced ejection fraction. Circulation 1985; 72: V102-9.




2020     |     www.medigraphic.com